How Far Analysts Bailed on Endo
When Endo International reported its first-quarter financial results on Thursday, earnings vastly underwhelmed, and analysts definitely had something to say about it.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 214
4 Major FDA Decisions Expected by June
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Analysts Adjust Predictions on Medivation Buyout Price
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
Intellia Therapeutics Enters the Market With a Bang
Intellia Therapeutics entered the market with a bang on Friday, blowing out its expected price range of $16 to $18.
How Guidance Sank Endo International
Endo International reported mixed first-quarter financial results after the markets closed on Thursday.
Is Pernix Therapeutics in a Race to Zero?
Pernix Therapeutics saw its shares hit a 52-week low in regular trading on Thursday after it reported its first-quarter financial results.
Oncobiologics Closes in on Market Entrance With Most Recent IPO Filing
Oncobiologics expects to price 5 million shares within the range of $11 to $13 per share in an initial public offering valued up to mroe than $74 million.
Merck Earnings Beat Estimates; More Acquisitions on Tap
Drug giant Merck reported mixed first-quarter 2016 results before markets opened Thursday morning.
3 Big Pharma Stocks With Credible Threats to Their Blockbusters
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates for generic…
Why Credit Suisse’s Neutral Rating on Teva Almost Sounds Like a Buy Rating
Credit Suisse's new Neutral rating on Teva Pharmaceutical Industries actually comes with significant upside.
Humana Earnings Beat Estimates but Fail to Impress Investors
Humana reported better-than-expected first-quarter financial results before the markets opened on Wednesday.
Can Gilead Shares Still Really Rise to $150?
Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon.
Viamet Pharma Announces Potential Pricing for IPO
Viamet Pharmaceuticals intends to price more than 5 million shares within the range of $14 to $16 per share for an initial public offering valued up to almost $105 million.
3 Underfollowed Infectious Disease Stocks That Deserve More Attention
Infectious diseases always have been a hot topic in biotech, but over the past half decade more capital has been drawn into the space.
Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar
Pfizer reported better-than-expected first-quarter 2016 results before markets opened Tuesday morning.